Merck Submits Ariad Drug to EU

Xconomy Boston — 

Cambridge, MA-based Ariad Pharmaceuticals (NASDAQ: ARIA) said today that its partner, Merck (NYSE: MRK) has submitted an application to the European Union for clearance to start selling ridaforolimus as a new treatment for sarcomas. Merck plans to submit its application for FDA approval soon, Ariad said. Data on a pivotal clinical trial for the new drug was presented in June at the American Society of Clinical Oncology. If approved by regulators, the sarcoma treatment will be Ariad’s first to reach the market.